Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics-Reference-Cited by-同舟云学术

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Published:2018-05-30 Issue:8 Volume:38 Page:737-750
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Moschetti Viktoria,Schlecker Christina,Wind Sven,Goetz Sophia,Schmitt Holger,Schultz Armin,Liesenfeld Karl-Heinz,Wunderlich Glen,Desch Michael

Funder

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s40261-018-0660-2/fulltext.html

Reference22 articles.

1. Evans JD, Bond GR, Meyer PS, et al. Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr Res. 2004;70(2–3):331–42.

2. Kurtz MM, Wexler BE, Fujimoto M, et al. Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. Schizophr Res. 2008;102(1–3):303–11.

3. Velligan DI, Mahurin RK, Diamond PL, et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25(1):21–31.

4. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119–36.

5. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158(9):1367–77.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives;Brain Sciences;2024-08-06

2. Interactions Involving Glycine and Other Amino Acid Neurotransmitters: Focus on Transporter-Mediated Regulation of Release and Glycine–Glutamate Crosstalk;Biomedicines;2024-07-08

3. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia;Biochemical Pharmacology;2024-05

4. Beyond dopamine: Novel strategies for schizophrenia treatment;Medicinal Research Reviews;2024-04-23

5. Antibiotics treatment promotes vasculogenesis in the brain of glioma-bearing mice;Cell Death & Disease;2024-03-13